A formulary strategy that moves with the market
Supporting your members and your long-term financial goals
Anyone who's navigated rush-hour traffic knows the fastest route isn't always the most direct one. That's why GPS considers the full journey, accounting for bottlenecks, detours and changing conditions to give you the best route. It monitors the road ahead and adjusts when it needs to.
Effective formulary management takes a similarly broad view. When a lower-cost therapy gains FDA approval and enters the market, it can create a significant savings opportunity for plan sponsors. But price alone doesn’t determine whether a formulary decision will deliver sustainable savings while preserving access to clinically appropriate care.
Clinical evidence, supply, provider adoption, member experience and the potential effect on utilization all help shape the outcome. And these factors vary across therapies and evolve over time.
A strong formulary strategy looks at the whole picture. That includes evaluating the full clinical landscape through the work of our Pharmacy and Therapeutics (P&T) Committee to help determine when to move quickly, when to take a more measured approach and when new developments warrant a fresh look.
What shapes a successful formulary decision?
-
Clinical evidence
Does the evidence support broad use, and how does the treatment fit within today's standards of care?
-
Cost
Will preferring the lower cost option create sustainable value?
-
Supply
Is enough product available to support demand?
-
Provider adoption
Will providers adopt the preferred therapy?
-
Member experience
How could formulation, ease of use and transition requirements affect members?
-
Utilization impact
Could the decision shift utilization to higher-cost or less-preferred treatment?
We all know a formulary is more than a list of preferred drugs. It's a tool for balancing affordability, access, clinical quality and member experience over time. That’s why it’s critical to have a PBM partner with the experience and clinical insight to understand how every decision could affect your plan and your members.
CVS Caremark works with you to shape an approach that supports member health while also advancing your long-term financial goals.
One goal, different paths: why market conditions matter
When biosimilars entered the market for Humira and Stelara, both presented significant opportunities to reduce costs and expand access to effective therapies.
Yet the market conditions surrounding each reference product were fundamentally different.
These examples highlight an important principle of formulary strategy: The right approach won’t look the same each time. It requires understanding the clinical, competitive and operational factors that influence adoption, then acting when conditions support savings, access and clinically appropriate care.
The Humira market was ready for rapid action
When biosimilar competition arrived for Humira, it had been one of the largest drivers of pharmacy spend for years across the CVS Caremark book of business. It was also typically the costliest prescription drug for self-funded health plans.*
Reliable supply, multiple approved treatment options and comprehensive transition support created the conditions for a successful conversion while helping members maintain uninterrupted access to care.
Recognizing the opportunity to help plan sponsors reduce costs, we moved quickly. We became the first PBM to remove Humira from our standard template formularies and prefer biosimilars, helping accelerate adoption across the market.
Biosimilars to Humira
93% of eligible utilization shifted to preferred biosimilar within one year*
$3.3B gross savings from adalimumab*
Stelara called for a more measured approach
Stelara presented a different set of market dynamics. As biosimilars entered the market, prescribing patterns were already shifting toward other, higher-cost therapies in the category. Moving before supply and provider adoption could support a broad transition risked shifting utilization away from Stelara altogether rather than toward its lower-cost biosimilars.
We took a more measured approach, closely monitoring supply readiness, provider adoption and utilization patterns. Once those conditions could support a successful transition, we removed Stelara from our commercial template formularies and preferred its biosimilars, helping capture savings while protecting member access.
Biosimilars to Stelara
98% prescriptions moved to preferred biosimilars within 3 months*
$155M anticipated annual net client savings*
Looking ahead to the next biosimilar opportunities
Helping clients optimize savings opportunities while preserving access to care for their members requires a forward-looking approach. We’re keeping a close eye on the pipeline and market conditions to monitor new developments, including anticipated biosimilars for Enbrel and Xolair.
As these markets take shape, understanding when conditions support a change will be key to determining strategy.
Evolving markets call for continuous reassessment
Sometimes, changing market conditions open the door to a different approach.
That’s what happened in the fast-moving weight management market, where new developments changed the equation for plan sponsors.
As weight management GLP-1s continue to gain momentum, plan sponsors face a difficult balance: providing access to effective therapies while managing category costs that can be difficult to sustain.
A bold move toward more sustainable coverage
In 2025, we removed Zepbound from our commercial template formularies while continuing to prefer Wegovy. Based on the clinical evidence and market dynamics at the time, our goal was to help more clients offer weight management coverage on a more sustainable basis.
A fresh look when the market shifted
We knew the weight management market would continue to evolve, so we monitored it closely. As new direct-to-consumer pricing models emerged, manufacturer list prices decreased and treatment options expanded, the opportunity for plan sponsors changed as well.
We reassessed the market and reintroduced Zepbound to our commercial template formularies, expanding the options available to plan sponsors as pricing and competitive conditions evolved.
That decision reflects the value of having an experienced partner that watches the market closely and acts as meaningful changes emerge.
Effective formulary management keeps moving
Markets keep moving, and the right formulary strategy needs to move with them. Like a GPS that adjusts to changing road conditions, formulary management works best when decisions reflect what's happening in the market today, while keeping an eye on what may be around the next turn.
Clinical evidence, provider adoption, member access, competition, supply and cost trends all matter. Some help explain the market as it exists today. Others can signal where it's headed tomorrow. With a PBM partner that understands how those factors come together, plan sponsors can make well-timed decisions that help protect access to care, manage costs and support greater value for their plans and members.
Let's look ahead together.
Contact your CVS Caremark account team to explore what changing market conditions could mean for your plan and how we can help you prepare for what’s next.
-
*FOR HUMIRA COSTLIEST PRESCRIPTION DRUG CLAIM: Humira Costliest Drug for Self-Funded Plans, But GLP-1s are Gaining Ground - MedBen Rx
-
*FOR 93% HUMIRA BIOSIMILAR ADOPTION CLAIM: CVS Health Analytics, 2026. CVS Commercial clients Apr 2024 – Dec 2025. P1017770425
-
*FOR $3.3B GROSS ADALIMUMAB SAVINGS CLAIM: CVS Health Analytics, 2026 for April 2024 - December 2025. CVS Commercial clients. P1017640325
-
*FOR 98% STELARA BIOSIMILAR ADOPTION CLAIM: Specialty Product Strategy Business Analytics, October 2026. P1020241126
-
*FOR $155M ANTICIPATED STELARA BIOSIMILAR SAVINGS CLAIM: Based on current modeling assumptions applicable to the Commercial template book of business. CVS Health Rebate Performance Management. P1019100326
-
*FOR XOLAIR AND ENBREL GROSS SALES CLAIM: U.S. Gross Sales 2024, IPD Analytics. Biosimilar Pipeline Report: 1H 2026, December 2025, accessed Feb. 2, 2026.
All data sharing complies with applicable law, our information firewall and any applicable contractual limitations. Savings projections are based on CVS Caremark data. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors.